|Research on Raynaud's
|The Role of Nitric Oxide in Raynaud's
The Vascular Microenvironment and Systemic Sclerosis. The role of the vascular microenvironment in the pathogenesis Systemic Sclerosis (SSc) is appreciated clinically as Raynaud's syndrome with capillary nail bed change. This manifestation of vasculopathy is used diagnostically in both limited and diffuse cutaneous subsets of SSc, and is thought to precede fibrosis. Tracy Frech. Int J Rheumatol, 2010. (Also see Vascular Involvement)
Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia. Raynauds syndrome, acrocyanosis and erythromelalgia are functional vascular diseases that differ with respect to prevalence, clinical picture, therapy, prognosis, and impairment of quality of life. Heidrich H. (PubMed) Vasa, 2010 Feb;39(1):33-41.
Apricus Biosciences Announces Last Patient Enrolled in RayVa(TM) Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma. The company expects to report top-line data in the third quarter of 2015 in advance of potentially moving RayVa into a pivotal Phase 2b trial following further guidance discussions with the FDA. GlobeNewswire, 06/15/2015.
Serum nitric oxide (NO) metabolites and disease activity in patients with systemic sclerosis. Serum NO(x) in SSc patients were elevated compared to healthy controls. Serum NO(x) level was determined by multiple factors including age, prednisolone use, and elevated pulmonary arterial pressure. (PubMed) Clin Rheumatol. 2008 Mar;27(3):315-22. Epub 2007 Aug 15. (Also see Raynaud's)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: